SCM
CRSP icon

Sterling Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Sterling Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.3K Sell
1,674
-1,363
-45% -$71.8K ﹤0.01% 1417
2026
Q1 		$144K Sell
3,037
-2,017
-40% -$106K ﹤0.01% 1282
2025
Q4 		$265K Sell
5,054
-677
-12% -$40.5K ﹤0.01% 1231
2025
Q3 		$371K Buy
5,731
+3,471
+154% +$199K 0.01% 1103
2025
Q2 		$110K Buy
+2,260
New +$87.5K ﹤0.01% 1341

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sterling Capital Management's CRSP Position: Q2 2026 in Review

Sterling Capital Management reduced its CRISPR Therapeutics (CRSP) stake by 45% in Q2 2026, selling an estimated $71.8K and leaving 1,674 shares worth $91.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Sterling Capital Management first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $371K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Sterling Capital Management held 1,674 shares of CRISPR Therapeutics worth $91.3K as of Q2 2026.
  • Sterling Capital Management sold 1,363 CRISPR Therapeutics shares in Q2 2026, an estimated $71.8K.
  • CRISPR Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1417 holding.
  • Sterling Capital Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's CRISPR Therapeutics position peaked at $371K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.